Sugisaki Kenji, Inoue Toshihiro, Yoshikawa Keiji, Kanamori Akiyasu, Yamazaki Yoshio, Ishikawa Shinichiro, Uchida Kenichi, Iwase Aiko, Araie Makoto
Department of Ophthalmology, International University of Health and Welfare, Mita Hospital, Tokyo, Japan; Department of Ophthalmology, University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Department of Ophthalmology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Ophthalmology. 2022 May;129(5):488-497. doi: 10.1016/j.ophtha.2021.11.025. Epub 2021 Dec 8.
To identify risk factors for further deterioration of central visual function in advanced glaucoma eyes.
Prospective, observational 5-year study.
Advanced glaucoma patients with well-controlled intraocular pressure (IOP), mean deviation (MD) of the Humphrey Field Analyzer (HFA) 24-2 program ≤-20 dB and best-corrected visual acuity (BCVA) of 20/40.
The HFA 10-2 test and BCVA examination were performed every 6 months, and the HFA 24-2 test was performed every 12 months for 5 years. The Cox proportional hazards model was used to identify risk factors for deterioration of HFA 10-2 and 24-2 results and BCVA.
Deterioration of HFA 10-2 results was defined by the presence of the same ≥3 points with negative total deviation slope ≤-1 dB/year at P < 0.01 on ≥3 consecutive tests, deterioration of HFA 24-2 results by an increase ≥2 in the Advanced Glaucoma Intervention Study score on ≥2 consecutive tests, and deterioration of BCVA by an increase of ≥0.2 logarithm of the minimum angle of resolution (logMAR) on ≥2 consecutive tests.
A total of 175 eyes of 175 patients (mean age, 64.1 years; mean baseline IOP, 13.2 mmHg; mean BCVA, 0.02 logMAR; mean HFA 24-2 and 10-2 MD, -25.9 and -22.9 dB, respectively) were included. The probabilities of deterioration in HFA 10-2 and 24-2 results and BCVA were 0.269 ± 0.043 (standard error), 0.173 ± 0.031, and 0.194 ± 0.033, respectively, at 5 years. Lower BCVA at baseline (P = 0.012) was associated significantly with further deterioration of HFA 10-2 results. Better HFA 24-2 MD (P < 0.001) and use of systemic antihypertensive agents (P = 0.009) were associated significantly with further deterioration of HFA 24-2 results, and a greater β-peripapillary atrophy area-to-disc area ratio (P < 0.001), use of systemic antihypertensive agents (P = 0.025), and lower BCVA (P = 0.042) were associated significantly with further deterioration of BCVA, respectively.
In advanced glaucoma eyes with well-controlled IOP, BCVA, β-peripapillary atrophy area-to-disc area ratio, and use of systemic antihypertensive agents were significant prognostic factors for further deterioration of central visual function.
确定晚期青光眼患者中心视力功能进一步恶化的危险因素。
前瞻性、观察性5年研究。
眼压控制良好、Humphrey视野分析仪(HFA)24-2程序平均偏差(MD)≤-20 dB且最佳矫正视力(BCVA)为20/40的晚期青光眼患者。
每6个月进行一次HFA 10-2检测和BCVA检查,每12个月进行一次HFA 24-2检测,持续5年。采用Cox比例风险模型确定HFA 10-2和24-2结果及BCVA恶化的危险因素。
HFA 10-2结果恶化定义为在连续≥3次检测中,出现相同的≥3个点且总偏差斜率为负≤-1 dB/年,P<0.01;HFA 24-2结果恶化定义为在连续≥2次检测中,青光眼干预研究评分增加≥2;BCVA恶化定义为在连续≥2次检测中,最小分辨角对数(logMAR)增加≥0.2。
共纳入175例患者的175只眼(平均年龄64.1岁;平均基线眼压13.2 mmHg;平均BCVA 0.02 logMAR;平均HFA 24-2和10-2 MD分别为-25.9和-22.9 dB)。5年时,HFA 10-2和24-2结果及BCVA恶化的概率分别为0.269±0.043(标准误)、0.173±0.031和0.194±0.033。基线时较低的BCVA(P = 0.012)与HFA 10-2结果的进一步恶化显著相关。较好的HFA 24-2 MD(P<0.001)和使用全身性抗高血压药物(P = 0.009)与HFA 24-2结果的进一步恶化显著相关,较大的β-视盘周围萎缩面积与视盘面积比值(P<0.001)、使用全身性抗高血压药物(P = 0.025)和较低的BCVA(P = 0.042)分别与BCVA的进一步恶化显著相关。
在眼压控制良好的晚期青光眼患者中,BCVA、β-视盘周围萎缩面积与视盘面积比值以及全身性抗高血压药物的使用是中心视力功能进一步恶化的重要预后因素。